Investigating Critical Issues in the Management of Patients with Severe Asthma




This program begins with an introduction to severe asthma and a review of the scope of issues in effective patient management. Following the introduction, a case study patient is presented, and a series of questions are asked to the learner to allow them to customize their participation. Key information on severe asthma phenotypes and endotypes, biomarker testing, evidence in support of biologic therapies, reduction of oral corticosteroid (OCS) use, and optimal management of patients with severe asthma are discussed by expert faculty.



John Oppenheimer, MD
Clinical Professor of Medicine
University of Medicine and Dentistry of New Jersey
Morristown, New Jersey


Reynold A. Panettieri, Jr., MD
Professor of Medicine
Robert Wood Johnson Medical School
Vice Chancellor, Clinical & Translational Science
Director, Rutgers Institute for Translational Medicine & Science
New Brunswick, New Jersey
Emeritus Professor of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania


Release date: November 26, 2019
Expiration date: November 26, 2020
Estimated time to complete activity: 1.0 hour(s)



This educational initiative has been designed for allergists, pulmonologists, internal medicine physicians, and specialty nurse practitioners and physician assistants involved in the management of patients with severe asthma.


Upon completion of this educational activity, participants should be able to:

  • Review severe asthma phenotypes and endotypes and conduct appropriate biomarker tests to differentiate between phenotypes in patients with severe asthma
  • Evaluate the latest evidence supporting the use of biologic therapies for the management of severe asthma
  • Incorporate into practice the most recent recommendations for the optimal management of patients with severe asthma
  • Implement strategies to minimize the use of OCS in patients with severe asthma

There are no fees for participating and receiving CME credit for this activity. During the period of November 26, 2019 through November 26, 2020, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.




Integrity Continuing Education is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


Integrity Continuing Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or


Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

John J. Oppenheimer, MD
Consulting Fees: GlaxoSmithKline, PLC; Kaléo, Inc.; Teva Pharmaceuticals USA
Contracted Research: AstraZeneca Pharmaceuticals LP; GlaxoSmithKline, PLC; Novartis Pharmaceuticals Corporation; Sanofi/Regeneron

Reynold A. Panettieri, Jr., MD
Consulting Fees: AstraZeneca Pharmaceuticals LP; MedImmune Inc.; Novartis Pharmaceuticals Corporation; Sanofi/Regeneron
Speakers Bureaus: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Boston Scientific; Sanofi/Regeneron; Teva Pharmaceuticals USA
Contracted Research: Amgen Inc.; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Genentech Inc.; Gilead Sciences, Inc.; MedImmune Inc.; RFIM; Sanofi/Regeneron; Theratrophix; Vertex Pharmaceuticals Incorporated

The Integrity CE planners and managers have nothing to disclose.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Sanofi Genzyme and Regeneron Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued).


Windows 98, 2000, XP, 2003, Vista, and 7
Internet Explorer 6/7
Firefox 2
Mozilla 1.7 or higher
Netscape 8.1 or higher
Flash Player 10

Mac OS X 10.3, 10.4
Safari 1.3 (Mac OS 10.3)
Safari 2.0 or higher (Mac OS 10.4)
Firefox 2
Flash Player 10
Use of Internet Explorer browser is not recommended.

Click here for more information on minimum system requirements.


The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.


Provided by Integrity Continuing Education, Inc.


Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Continue to Pretest